|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA47
|
|
gptkbp:brand
|
gptkb:Saphnelo
|
|
gptkbp:CASNumber
|
1620458-25-8
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
serious hypersensitivity to anifrolumab
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:halfLife
|
~18 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
anifrolumab
|
|
gptkbp:indication
|
moderate to severe systemic lupus erythematosus
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:IgG1_kappa
|
|
gptkbp:mechanismOfAction
|
type I interferon receptor antagonist
|
|
gptkbp:pregnancyCategory
|
not assigned (consult physician)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
bronchitis
herpes zoster
upper respiratory tract infection
infusion-related reactions
|
|
gptkbp:target
|
gptkb:interferon_alpha/beta_receptor_subunit_1_(IFNAR1)
|
|
gptkbp:UNII
|
6QY1D3102P
|
|
gptkbp:usedFor
|
gptkb:systemic_lupus_erythematosus
|
|
gptkbp:bfsParent
|
gptkb:Saphnelo
|
|
gptkbp:bfsLayer
|
7
|